Programmed Cell Death Ligand 2 Archives | MSD Oncology Clinical Trials

Study Keyword: Programmed Cell Death Ligand 2

This study will evaluate the safety and efficacy of favezelimab (MK-4280) in combination with pembrolizumab (MK-3475) using a non-randomised study design in participants with the following haematological malignancies:

classical Hodgkin lymphoma (cHL)
diffuse large B-cell lymphoma (DLBCL)
indolent non-Hodgkin lymphoma (iNHL)

This study will also evaluate the safety and efficacy of pembrolizumab or favezelimab administered as monotherapy in participants with cHL using a 1:1 randomised study design.

The study will have 2 phases: a safety lead-in and an efficacy expansion phase. The recommended Phase 2 dose (RPTD) will be determined in the safety lead-in phase by evaluating dose-limiting toxicities.

There is no primary hypothesis for this study.

Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab and Pembrolizumab in Participants With Haematologic Malignancies

March 10, 2022

By Support_Clique

This study will evaluate the safety and efficacy of favezelimab (MK-4280) in combination with pembrolizumab (MK-3475) in participants with the following hematological malignancies: classical Hodgkin lymphoma (cHL) diffuse large B-cell lymphoma

Pembrolizumab Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma

March 7, 2022

By clique_admin

This is a randomized, double-blind, study that compares pembrolizumab (MK-3475) with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone